Philip Morris International Highlights Novel E-Vapor Technology in Latest Scientific Update for Smoke-Free
Products
Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) today released its second Scientific Update for Smoke-Free
Products, a regular publication on its research efforts to develop and assess a range of potentially reduced-risk alternatives to
cigarettes. The full issue is available here: https://www.pmiscience.com/news/smoke-free-products-scientific-update.
This issue of the Scientific Update focuses on novel approaches to e-vapor products. Technology and innovation can improve user
experience and continuously enhance a product’s potential to present less risk of harm than smoking. The focus of the issue details
the product design and manufacturing behind MESH, the new generation of e-vapor technology PMI is currently test marketing
in Birmingham (UK). MESH is one of the four smoke-free product types developed by PMI, along with IQOS.
Prof. Manuel Peitsch, PMI’s Chief Scientific Officer, explains: “PMI is working to progressively transition its existing
cigarette business to smoke-free products. By offering a diverse portfolio of innovative and scientifically substantiated
alternatives, we believe we can accelerate the switching of an even greater number of adult smokers who would otherwise continue to
smoke and have a positive impact on public health.”
Michele Cattoni, PMI’s VP Technology and Operations, further elaborates on the Company’s efforts: “Technological innovation is
at the heart of PMI’s efforts to create a smoke-free future. We have developed an e-vapor product which, like our other smoke-free
technologies, incorporates the highest manufacturing and design standards to ensure the consistency and quality of the generated
vapor.”
Beyond the development behind PMI’s MESH proprietary technology, the Update provides an overview of its assessment to
date. The issue also covers the latest studies, key peer-reviewed publications and presentations at scientific conferences. It is
an important complement to PMI’s ongoing efforts to share its latest science, which include a dedicated website (www.pmiscience.com).
PMI’s extensive research and assessment program is inspired by the well-recognized practices of the pharmaceutical industry and
in line with guidance of the U.S. FDA for Modified-Risk Tobacco Products (MRTPs). The Company today employs over 400 world-class
scientists, engineers and experts who conduct rigorous research, including laboratory and clinical studies, as well as
ground-breaking systems toxicology. The assessment program also includes studies on actual product use and correct understanding of
product communications, as well as post-market research.
About Philip Morris International Inc. (“PMI”)
PMI is the world’s leading international tobacco company, with six of the world's top 15 international brands and products sold
in more than 180 markets. In addition to the manufacture and sale of cigarettes, including Marlboro, the number one global
cigarette brand, and other tobacco products, PMI is engaged in the development and commercialization of reduced-risk products
(“RRPs”). RRPs is the term PMI uses to refer to products that present, are likely to present, or have the potential to present less
risk of harm to smokers who switch to these products versus continued smoking. Through multidisciplinary capabilities in product
development, state-of-the-art facilities, and industry-leading scientific substantiation, PMI aims to provide an RRP portfolio that
meets a broad spectrum of adult smoker preferences and rigorous regulatory requirements. For more information, see www.pmi.com and www.pmiscience.com.
![](http://cts.businesswire.com/ct/CT?id=bwnews&sty=20170522005754r1&sid=mstr1&distro=nx&lang=en)
Media enquiries
Philip Morris International media office
T: +41 (0)58 242 4500
E: media@pmi.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170522005754/en/